Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Lingmin Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8227-2880; OpenAlex author ID A5037321024. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 4 papers · 2025: 4 papers · 2026: 2 papers

Papers 11

  1. Anti-PD-1 blockade reverses low-intensity electric stimulation-driven pancreatic cancer progression. Co-author DOI 10.3389/fimmu.2026.1793161↗
  2. Efficacy of immune checkpoint inhibitors combined with different chemotherapy in recurrent pancreatic cancer: a retrospective study. First author DOI 10.3389/fimmu.2026.1841783↗
  3. Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC. Co-author DOI 10.1016/j.tranon.2024.102206↗
  4. Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.2147/jir.s519779↗
  5. Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation. Co-author DOI 10.3389/fimmu.2025.1546242↗
  6. Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreati… Co-author DOI 10.3389/fimmu.2025.1688440↗
  7. Triglyceride-glucose index and glycemic dynamics in pancreatic ductal adenocarcinoma: implications for disease progression and prognosis. First author DOI 10.1186/s12967-024-05524-w↗
  8. Treatment of locally advanced pancreatic cancer with irreversible electroporation and intraoperative radiotherapy. Co-author DOI 10.21037/hbsn-24-526↗
  9. Blockades Adenosine Receptor 2B Suppresses Pancreatic Adenocarcinoma Progression by Inhibiting Leukemia Inhibitory Factor Secretion from Macrophages Co-author DOI 10.21203/rs.3.rs-4829619/v1↗
  10. Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analy… Co-author DOI 10.3389/fmed.2024.1486750↗
  11. Long-term effects of total vs. partial pancreatectomy among patients with pancreatic cancer: a population-based study. Co-author DOI 10.21037/atm-22-2217↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pu Xi · 7 shared papers, 2024–2026 · strength 1.90
  2. Zehui Yao · 7 shared papers, 2024–2026 · strength 1.86
  3. Dailei Qin · 6 shared papers, 2024–2025 · strength 1.56
  4. Shengping Li · 4 shared papers, 2024–2026 · strength 1.12
  5. Chaobin He · 3 shared papers, 2025–2026 · strength 0.88
  6. Shengping Li · 3 shared papers, 2024–2026 · strength 0.83
  7. Ran Wei · 3 shared papers, 2024–2025 · strength 0.77
  8. Shengping Li · 2 shared papers, 2024–2025 · strength 0.49
  9. Qiang Tao · 2 shared papers, 2022–2026 · strength 0.44
  10. Yunda Song · 1 shared paper, 2024 · strength 0.28
  11. Xin Huang · 1 shared paper, 2024 · strength 0.24
  12. Yun Zheng · 1 shared paper, 2022 · strength 0.13
  13. Andreas Minh Luu · 1 shared paper, 2022 · strength 0.13
  14. Zhiwen Yang · 1 shared paper, 2022 · strength 0.13
  15. Yong Wang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.